CINECA IRIS Institutional Research Information System

DI MUNNO, OMBRETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.740
AS - Asia 3.274
EU - Europa 2.496
SA - Sud America 404
AF - Africa 245
Continente sconosciuto - Info sul continente non disponibili 61
OC - Oceania 7
Totale 12.227
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.523
CN - Cina 1.047
SG - Singapore 927
IT - Italia 817
HK - Hong Kong 557
SE - Svezia 366
BR - Brasile 349
VN - Vietnam 249
BG - Bulgaria 248
UA - Ucraina 239
DE - Germania 210
CA - Canada 192
FI - Finlandia 139
TR - Turchia 128
KR - Corea 123
CH - Svizzera 121
RU - Federazione Russa 100
SN - Senegal 96
FR - Francia 94
NG - Nigeria 94
IN - India 82
GB - Regno Unito 77
JP - Giappone 33
AT - Austria 32
CI - Costa d'Avorio 25
BD - Bangladesh 21
IQ - Iraq 17
AR - Argentina 15
BE - Belgio 14
ZA - Sudafrica 13
PK - Pakistan 10
UZ - Uzbekistan 10
EC - Ecuador 9
IR - Iran 9
MX - Messico 9
ID - Indonesia 8
SA - Arabia Saudita 8
VE - Venezuela 8
AU - Australia 6
CR - Costa Rica 6
IE - Irlanda 6
SI - Slovenia 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
MA - Marocco 5
NL - Olanda 5
TW - Taiwan 5
LB - Libano 4
LT - Lituania 4
MM - Myanmar 4
PE - Perù 4
PH - Filippine 4
PY - Paraguay 4
BO - Bolivia 3
CO - Colombia 3
EG - Egitto 3
EU - Europa 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
RO - Romania 3
UY - Uruguay 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
ES - Italia 2
GR - Grecia 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
LK - Sri Lanka 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
RS - Serbia 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
JO - Giordania 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PR - Porto Rico 1
PT - Portogallo 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
YT - Mayotte 1
ZW - Zimbabwe 1
Totale 12.169
Salva come PNG Salva come JPEG
Città #
Ashburn 588
Hong Kong 545
Woodbridge 491
Singapore 490
Santa Clara 481
Chandler 430
Ann Arbor 414
Milan 407
Fairfield 333
Jacksonville 307
Sofia 246
San Jose 236
Beijing 228
Houston 225
Shanghai 207
Ottawa 176
Hefei 161
Dallas 150
New York 126
Seoul 123
Wilmington 122
Seattle 118
Bern 117
Cambridge 115
Boardman 101
Nanjing 99
Dakar 96
Lagos 94
Lawrence 94
Princeton 94
Izmir 86
Medford 75
Lauterbourg 74
Los Angeles 64
Jüchen 56
Ho Chi Minh City 53
Council Bluffs 52
Nanchang 52
Buffalo 50
Des Moines 42
Rome 42
Hanoi 41
Dong Ket 40
Dearborn 36
Istanbul 36
Helsinki 34
Vienna 32
Tokyo 31
Abidjan 25
Pune 25
São Paulo 24
Bremen 23
Grafing 23
Ogden 22
Kunming 21
San Diego 21
Shenyang 21
Redwood City 19
Rio de Janeiro 18
Hebei 17
Changsha 15
Brussels 14
Munich 14
Orange 14
Redondo Beach 14
Frankfurt am Main 13
Orem 13
Serra 12
Boulder 11
Hangzhou 11
Jiaxing 11
Auburn Hills 10
Leipzig 10
Norwalk 10
Tianjin 10
Fuzhou 9
Mumbai 9
Tashkent 9
Curitiba 8
Haiphong 8
Lanzhou 8
Brasília 7
Columbus 7
Florence 7
Ardabil 6
Baghdad 6
Jinan 6
Johannesburg 6
Padova 6
Paris 6
Toronto 6
Turku 6
Changchun 5
Chennai 5
Da Nang 5
Denver 5
Greifswald 5
Porto Alegre 5
Salvador 5
San Mateo 5
Totale 8.911
Salva come PNG Salva come JPEG
Nome #
The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. 213
Prevenzione e trattamento dell’osteoporosi indotta dagli inibitori dell’aromatasi. 195
Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass 192
Prevention of glucocorticoid-induced osteopenia: Effect of oral 25-hydroxyvitamin D and calcium 188
Effects of glucocorticoid treatment on focal and systemic bone loss in rheumatoid arthritis 181
Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. 180
Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. 179
Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients 177
Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. 174
Lung function in essential mixed cryoglobulinemia: a short-term follow-up. 174
[Renal tubular acidosis in essential mixed cryoglobulinemia]. 171
Personalization of biologic therapy in patients with rheumatoid arthritis: Less frequently accounted choice-driving variables 168
Vitamin D status and response to treatment in post-menopausal osteoporosis 167
Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study 166
Determinants of bone turnover markers in healthy premenopausal women 166
Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study 165
Determinants and Effects of Vitamin D Supplementation on Serum 25-Hydroxy-Vitamin D Levels in Patients with Rheumatoid Arthritis. 163
Lung involvement in essential mixed cryoglobulinemia. 162
Quantitative ultrasound calcaneous measurements: normative data for the Italian population. the ESOPO study 162
Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia 159
The effect of age,weight, and lifestyle factors on calcaneal quantitative ultrasound: the ESOPO study 158
Genetic epidemiology of Paget's disease of bone in italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone 158
Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss 157
Long-term prospective study of osteoporotic patients treated with percutaneous vertebroplasty after fragility fractures 156
Determinants of adherence to osteoporosis treatment in clinical practice 154
Glucocorticoid-induced osteoporosis: 2013 update. 153
Diagnostica strumentale: la densitometria ossea 152
Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over two years 151
Risk factors for osteoporosis in female patients with systemic lupus erythematosus 150
Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment. (Osteoporosi da glucocorticoidi e malattie reumatiche. Patogenesi, prevenzione e trattamento) 149
Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability 148
Deflazacort versus Methylprednisolone in Polymyalgia Rheumatica. Reply 147
Efficacy of risedronate on clinical vertebral fractures within six months 142
How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study 141
Reduced bone mass and normal calcium metabolism in patients with systemic sclerosis 140
Bisfosfonati e osteoporosi da glucocorticoidi up-to-date 2005 140
A multicenter cross-sectional study on bone mineral density in rheumatoid arthritis 140
Osteoporosi e malattie reumatiche: nuove opportunità terapeutiche. Up-to-date 2008 137
Clinical equivalence between deflazacort oral drops and tablets in active rheumatoid arthritis 137
Effects of short-term, high dose, Heparin therapy on biochemical markers of bone resorption 136
Effetti scheletrici ed extrascheletrici della vitamina D 136
Glucocorticoid-induced osteoporosis: 2013 update. 136
Single infusion of neridronate (6-amino-1hydroxy-hexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthrites:Effects on disease activity and bone resorption markers 130
Optimizing Bisphosphonate Treatment Outcomes in Postmenopausal Osteoporosis: Review and Italian Experience 129
Il dolore cronico nelle malattie reumatiche. Fisiopatologia e indicazioni di terapia. 129
La salute dell’osso dall’infanzia all’età adulta 128
Approccio diagnostico dell’osteoporosi postmenopausale 126
High rate of vertebral refracture after vertebroplasty in patients taking glucocorticoids: a prospective two-year study 126
Association of quantitative heel ultrasound with history of osteoporotic fractures in elderly men: The ESOPO study 125
I percorsi diagnostico-terapeutici assistenziali nella gestione del paziente con frattura. 125
Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate 123
Long-term prospective study of osteoporotic pacients treated with percutaneous vertebroplasty after fragility fractures. 123
Efficacy of ibandronate: a long term confirmation 122
Epidemiologia dell’osteoporosi da glucocorticoidi 122
Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description 122
Intramuscular neridronate in postmenopausal women with low bone mineral density 122
Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis 121
La vitamina D attraverso un secolo 120
Osteoporosi e malattie reumatiche: terapie di fondo 115
Ipovitaminosi D nell’anziano in Italia e la sua prevenzione 114
Multicentric Castleman's disease in a patient with primary Sjögren's syndrome. 112
Fisiopatologia dell’osteoporosi da glucocorticoidi e bisfosfonati. Up-to-date 2006 111
Study of vitamin D status of rheumatoid arthritis patients. (Studio dello stato vitaminico D in pazienti affetti da artrite reumatoide. Razionale e disegno della rilevazione cross-sectional programmata dal gruppo SIR per lo studio dell’osteoporosi e delle malattie metaboliche dello scheletro) 110
Terapia dell’osteoporosi. Presente e futuro 109
Incidenza e conseguenze dell’ipovitaminosi D. Up-to-date 2007 107
Razionale delle future terapie dell’osteoporosi 105
Bisfosfonati ed effetti scheletrici degli inibitori dell’aromatasi 104
Prevenzione e trattamento dell’osteoporosi indotta da glucocorticoidi nella realtà italiana e in quella internazionale. Rassegna 104
Eventi avversi dei bisfosfonati 103
Sistema nervoso autonomo e densità minerale ossea: studio dei polimorfismi dei recettori β1 e β2-adrenergici in una popolazione femminile 103
Ibandronato : conferma dell’efficacia a lungo termine 101
Meccanismi di rimodellamento osseo nelle malattie reumatiche 101
Bioelectrical impedance analysis (BIA) is a reliable method to evaluate lean body mass in maintenance hemodialysis patients: comparison with dual-energy emission x-rays absorptiometry (DXA). 99
Gli effetti avversi della terapia dell’osteoporosi 99
Il risedronato 98
Risedronato e trattamento dell’osteoporosi 98
Nuove opportunità di prevenzione e trattamento del’osteoporosi indotta da glucocorticoidi 98
Deflazacort vs. methylprednisolone in Polymyalgia Rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens 98
Minor connectivitis and the mixed connective tissue disease 98
Update sull’osteoporosi cortisonica 96
Vitamina D e malattie reumatiche 96
L’osteoporosi nelle malattie reumatiche 95
Farmaci biologici antireumatici 95
Osteoporosi : i farmaci efficaci per combatterla ci sono ma vanno presi e presi correttamente! 91
Nuove frontiere farmacologiche: l’osteoporosi 91
Methotrexate and bone mass 91
Influenza sulla funzione cartilaginea e sulle malattie degenerative articolari delle adipochine 87
Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study 87
Liver involvement in essential mixed cryoglobulinemia. 87
Effetti scheletrici della vitamina D 87
L’osteoporosi nelle malattie reumatiche 84
Osteoporosi : terapie a confronto. Introduzione 82
Osteociti e vascolarizzazione ossea nella fragilità scheletrica indotta da glucocorticoidi. 80
Prevenzione e trattamento dell’osteoporosi indotta da glucocorticoidi: recenti evidenze 78
Totale 12.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.288
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.288
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022803 0 74 10 71 172 109 6 43 31 9 55 223
2022/20231.254 148 110 83 124 209 187 2 81 257 5 42 6
2023/20241.190 241 169 156 101 168 159 21 32 17 9 37 80
2024/20252.652 6 104 9 120 322 260 301 158 257 350 272 493
2025/20262.211 159 326 232 143 247 228 365 87 98 193 90 43
2026/202783 49 34 0 0 0 0 0 0 0 0 0 0
Totale 12.227